• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Rezolute And 3 Other Penny Stocks Insiders Are Buying

    2/21/24 8:26:59 AM ET
    $BBGI
    $CIA
    $RVP
    $RZLT
    Broadcasting
    Consumer Discretionary
    Life Insurance
    Finance
    Get the next $BBGI alert in real time by email

    The Dow Jones index closed lower by more than 60 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Retractable Technologies

    • The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw acquired a total of 21,687 shares an average price of $1.28. To acquire these shares, it cost around $27,768.
    • What’s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first nine months of 2023.
    • What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.

    Citizens

    • The Trade: Citizens, Inc. (NYSE:CIA) President and CEO Gerald Shields acquired a total of 29,182 shares at at an average price of $3.00. To acquire these shares, it cost around $87,546.
    • What’s Happening: The company said total revenues rose to $59.4 million in the third quarter from $56.2 million in the year-ago period.
    • What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.

    Check This Out: Top 4 Tech Stocks That May Crash This Month

    Beasley Broadcast Group

    • The Trade: Beasley Broadcast Group, Inc. (NASDAQ:BBGI) Chief Operating Officer Brian E Beasley acquired a total of 1,200 shares at an average price of $0.85. The insider spent around $1,020 to buy those shares.
    • What’s Happening: Beasley Broadcast posted downbeat fourth-quarter sales.
    • What Beasley Broadcast Group Does: Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States.

    Rezolute

    • The Trade: Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans acquired a total of 50,900 shares at an average price of $1.35. The insider spent around $66,741 to buy those shares.
    • What’s Happening: Rezolute posted a narrower-than-expected quarterly loss.
    • What Rezolute Does: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies.


    Don’t forget to check out our premarket coverage here

     

    Get the next $BBGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBGI
    $CIA
    $RVP
    $RZLT

    CompanyDatePrice TargetRatingAnalyst
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    Rezolute Inc.
    $RZLT
    11/5/2024$12.00Outperform
    Wedbush
    Rezolute Inc.
    $RZLT
    8/27/2024$11.00Buy
    Guggenheim
    Rezolute Inc.
    $RZLT
    7/17/2024$13.00Buy
    BTIG Research
    Rezolute Inc.
    $RZLT
    6/4/2024$14.00Buy
    Craig Hallum
    Rezolute Inc.
    $RZLT
    4/9/2024$8.00Buy
    Maxim Group
    More analyst ratings

    $BBGI
    $CIA
    $RVP
    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

    REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025. Congenital Hyperinsulinism (HI) In December 2025, Rezolute reported topline results from sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI. The study did not meet its primary or key secondary endpoints. The study demonstrated reductions from baseline

    2/12/26 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglyc

    2/4/26 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

    Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today shared observations from the Phase 3 sunRIZE study in patients with congenital HI and provided details on the treatment of tumor HI patients with ersodetug under the Company's EAP. Congenital HI While sunRIZE did not meet its primary (hypoglycemi

    1/7/26 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBGI
    $CIA
    $RVP
    $RZLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:13:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron bought $79,578 worth of shares (45,000 units at $1.77), increasing direct ownership by 11% to 415,900 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/15/25 7:35:57 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBGI
    $CIA
    $RVP
    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Wedbush with a new price target

    Wedbush downgraded Rezolute from Outperform to Neutral and set a new price target of $1.00

    12/11/25 10:36:07 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBGI
    $CIA
    $RVP
    $RZLT
    SEC Filings

    View All

    SEC Form 10-Q filed by Rezolute Inc.

    10-Q - Rezolute, Inc. (0001509261) (Filer)

    2/12/26 4:36:52 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Rezolute, Inc. (0001509261) (Filer)

    2/12/26 4:13:20 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Rezolute Inc.

    SCHEDULE 13G - Rezolute, Inc. (0001509261) (Subject)

    2/11/26 2:01:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBGI
    $CIA
    $RVP
    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Taylor Mary increased direct ownership by 1% to 48,364 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:29:36 AM ET
    $CIA
    Life Insurance
    Finance

    Davis Cynthia H increased direct ownership by 0.93% to 45,967 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:28:28 AM ET
    $CIA
    Life Insurance
    Finance

    Davis Jerry increased direct ownership by 0.99% to 73,165 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:27:24 AM ET
    $CIA
    Life Insurance
    Finance

    $BBGI
    $CIA
    $RVP
    $RZLT
    Financials

    Live finance-specific insights

    View All

    Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

    Retractable Technologies, Inc. ("Retractable") (NYSE:RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning October 1, 2025 through December 31, 2025. The dividends will be paid on January 20, 2026 to shareholders of record as of the close of business on January 10, 2026. Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and

    12/30/25 4:14:00 PM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

    Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI). The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self

    12/11/25 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BEASLEY BROADCAST GROUP REPORTS THIRD QUARTER REVENUE OF $51.0 MILLION

    NAPLES, Fla., Nov. 10, 2025 /PRNewswire/ -- Beasley Broadcast Group, Inc. (NASDAQ:BBGI) ("Beasley" or the "Company"), a multi-platform media company, today announced operating results for the three-month period ended September 30, 2025. For further information, the Company has posted a presentation to its website regarding the third quarter highlights and accomplishments that management will review on today's conference call. Third Quarter Financial Highlights In millions, except per share data      Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2024 2025 2024

    11/10/25 7:00:00 AM ET
    $BBGI
    Broadcasting
    Consumer Discretionary

    $BBGI
    $CIA
    $RVP
    $RZLT
    Leadership Updates

    Live Leadership Updates

    View All

    Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

    REDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced the appointment of Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. "We're thrilled to welcome Sunil to our leadership team at such a pivotal point as we advance ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "His proven track record of successfully bringing therapies to patients across multiple therapeutic areas, including four ultr

    8/20/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

    sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. "The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are p

    5/13/25 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

    REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p

    3/26/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBGI
    $CIA
    $RVP
    $RZLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 10:04:23 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/13/24 5:31:40 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care